GHK-Cu — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Cutaneous wound healing and tissue repair
Anchor outcome. Time to complete closure.
Effect as recorded. Small controlled dermatological studies report improvements in skin roughness, wrinkle depth and collagen density with topical application over 12 weeks; small samples; instrument-based endpoints.[1,2]
Certainty. Low certainty The topical dermatological evidence is the strongest in this compound's file. It is nonetheless small-sample, mostly industry-conducted, and uses surrogate instrument endpoints.
Contributing trials. GHKCU-TOPICAL-1 · GHKCU-TOPICAL-2. Full structured abstracts are published for each.
Full evidence extract for cutaneous wound healing and tissue repair · Indication assessment
§3.2Biological ageing and healthspan endpoints
Anchor outcome. Epigenetic age acceleration.
Effect as recorded. No randomised human evidence for any systemic ageing endpoint; —.[2,3]
Certainty. Very low certainty The declining-with-age plasma concentration is an observation, not evidence of an intervention effect.
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for biological ageing and healthspan endpoints · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 2018;19(7):1987. doi:10.3390/ijms19071987 · PMID 29986520
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- United States Pharmacopeial Convention. General Chapter ⟨788⟩ Particulate Matter in Injections. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.